NewBiotics preclinical data

NewBiotics said that NB2001 was 30 times more potent than ampicillin in inhibiting the growth of non-resistant E. coli bacteria in vitro, and also was more effective against bacteria resistant to either ampicillin or SmithKline Beecham's Augmentin amoxicillin/clavulanate. The company also said that NB2001 had activity similar to vancomycin in inhibiting growth of Staphylococcus aureus bacteria. Data were presented at the International Conference on Emerging Infectious Diseases in Atlanta. ...